Overactivation of STAT3 by interferon-alpha may negatively influence disease outcome in melanoma patients

被引：0
|
作者：
Humpolikova, L. Adamkova [1 ]
Kovank, A. [2 ]
Dusek, L. [3 ]
Lauerova, L. [1 ]
Boudny, V. [1 ]
Kovarik, J. [1 ]
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Acad Sci Czech Republic, Inst Biophys, CS-61265 Brno, Czech Republic
[3] Inst Biostat & Analyses, Brno, Czech Republic
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 09期
关键词：
D O I：
10.1016/S1359-6349(08)71728-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [1] Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein
    Humpolikova-Adamkova, L.
    Kovarik, J.
    Dusek, L.
    Lauerova, L.
    Boudny, V.
    Fait, V.
    Fojtova, M.
    Krejci, E.
    Kovarik, A.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (07) : 1315 - 1323
  • [2] An analysis of STAT3 polymorphism on outcomes of interferon-alpha treatment in patients with metastatic renal cell carcinoma.
    Eto, M.
    Kamba, T.
    Miyake, H.
    Fujisawa, M.
    Yoshida, K.
    Uemura, H.
    Tsukamoto, T.
    Katsuoka, Y.
    Matsubara, A.
    Nishimura, K.
    Nakamura, T.
    Ogawa, O.
    Naito, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Use of STAT3 polymorphisms to predict overall survival in patients treated with interferon-alpha for metastatic renal cell carcinoma.
    Eto, Masatoshi
    Kamba, Tomomi
    Miyake, Hideaki
    Fujisawa, Masato
    Kamai, Takao
    Uemura, Hirotsugu
    Tsukamoto, Taiji
    Azuma, Haruhito
    Matsubara, Akio
    Nishimura, Kazuo
    Nakamura, Tsuyoshi
    Ogawa, Osamu
    Naito, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] SIPAR negatively regulates STAT3 signaling and inhibits progression of melanoma
    Ren, Fangli
    Su, Fuqin
    Ning, Hongxiu
    Wang, Yangmeng
    Geng, Yongtao
    Feng, Yarui
    Wang, Yinyin
    Zhang, Yanquan
    Jin, Zhe
    Li, Yi
    Jia, Baoqing
    Chang, Zhijie
    CELLULAR SIGNALLING, 2013, 25 (11) : 2272 - 2280
  • [5] HYPERTRIGLYCERIDEMIA MAY BE SEVERE IN CML PATIENTS TREATED WITH INTERFERON-ALPHA
    PENARRUBIA, MJ
    STEEGMANN, JL
    LAVILLA, E
    CASADO, F
    REQUENA, MJ
    PICO, M
    ARRANZ, R
    FERNANDEZRANADA, JM
    AMERICAN JOURNAL OF HEMATOLOGY, 1995, 49 (03) : 240 - 241
  • [6] Influence of pegylated interferon-alpha on the nitric oxide system in high-risk melanoma patients
    Fekkes, D
    Bannink, M
    Kruit, WHJ
    Sleijfer, S
    Mulder, PGH
    Eggermont, AMM
    Stoter, G
    Van Gool, AR
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S408 - S408
  • [7] CIRCULATING INTERFERON-ALPHA IN PATIENTS WITH KYASANUR FOREST DISEASE
    SATHE, PS
    DANDAWATE, CN
    SHARADAMMA, K
    GHOSH, SN
    INDIAN JOURNAL OF MEDICAL RESEARCH SECTION A-INFECTIOUS DISEASES, 1991, 93 : 199 - 201
  • [8] Interferon-alpha in the management of patients with Behcet's disease
    Yang, David S. F.
    Taylor, Simon R. J.
    Lightman, Sue L.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (10) : 575 - +
  • [9] Influence of interferon-alpha on lymphocyte subpopulations in Behcet's disease
    Treusch, M
    Stübiger, N
    Vonthein, R
    Baur, M
    Koch, S
    Günaydin, I
    Kanz, L
    Zierhut, M
    Kötter, I
    ADAMANTIADES-BEHCET'S DISEASE, 2003, 528 : 533 - 535
  • [10] Influence of immunotherapy with interferon-alpha on serum amino acids, biopterin and neopterin in high risk melanoma patients
    Van Gool, AR
    Fekkers, D
    Kruit, WHJ
    Ten Hagen, TLM
    Bannink, M
    Maes, M
    Eggermont, AMM
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S242 - S242
12345